Méndez OA

Language: Spanish
References: 18
Page: 182-187
PDF size: 115.88 Kb.

ABSTRACT

Treatment of heart failure has been successfully target biologically, to counteract deleterious effects resulting from neuroendocrine activation, with the use of several agents (e.g., angiotensineconverting enzyme inhibitors, beta-adrenergic receptor blockers, spironolactone), that provide benefical effects, demonstrated in multicentric trials in controlled populations. However, this mid-term benefit, becomes less effective with time, resulting in progression of the disease to terminal stages and death. The purpose of this paper is to review other pathophysiologic pathways and the potential application of preventive measures to be incorporated in the standardized treatment of heart failure.

REFERENCES

1. HUNT SA, ET AL: ACC/AHA Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article. Circulation 2005; 112: 1825-1852.

2. FOO RS, MANI K, KITSIS RN: Death begets failure in the heart. J Clin Invest 2005: 115; 565-571. 3. BENNETT MR: Apoptosis in the cardiovascular system. Heart 2002; 87: 480-487.

3. OLIVETTI G, ET AL: Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.

4. WENCKER D, ET AL: A mechanistic role for cardiomyocyte apoptosis in heart failure. Cell; 2003: 1497-1504.

5. MACCARTHY PA, SHAH AM: Oxidative stress and heart failure. Coronary Artery Disease. 2003; 14: 109-113.

6. MCMURRAY J, CHOPRA M, ABDULLAHI, SMITH WE, DARGIE HJ: Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493-1498.

7. XIE YW, KAMINSKI PM, WOLIN MS: Inhibition of cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation. Circ Res 1998; 82: 891-897.

8. HARE JM: Oxidative stress and apoptosis in heart failure progression. Circ Res 2001; 89: 198-200.

9. YUSUF F, DAGENIAS G, POGUE J, BOSH J, SLIGHT P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160.

10. PARRILLO JE, BURCH C, SHELLHAMER JH, ET AL. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985; 76: 1539-53.

11. KAPADIA S, TORRE-AMIONE G, YOKOHAMA T, ET AL: TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am J Physiol 1995; 268: H517-25.1

12. BOZKURT B, TORRE-AMIONE G, WARREN MS, ET AL: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.

13. BAUERSACHS J, FRACCAROLLO D, SCHAFER A, ERTL G: Angiotensin-Converting Enzyme Inhibition and Endothelin Antagonism for Endotelial Dysfunction in Heart Failure: Mono- or Combination Therapy. J Cardiovasc Pharmacol 2002; 40: 594-600.

14. KAYE D, AHLERS B, AUTELIANOD, CHIN-DUSTIN J. In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure. Circulation 2000; 102: 2707-2712.

15. LÓPEZ A, CASADO S: Heart Failure, Redox Alterations, and Endotelial Dysfunction. Hypertension 2001; 38: 1400-1405.

16. ROSSIG L, HOFFMANN J, HUGEL B, MALLAT Z, HAASE A, FREYSSINET JM, ET AL: Vitamin C Inhibits Endothelial Cell Apoptosis in Congestive Heart Failure. Circulation 2001; 104: 2182-2187.

17. FANG Z, MARWICK T: Vascular dysfunction ang heart failure: Epiphenomenon or etiologic agent? Am Heart J 2002; 143: 383-390.

18. MACDONALD J, KENNEDY N, STRUTHERS A: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-770.